These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15929702)

  • 1. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
    Resino S; Galán I; Pérez A; Ramos JT; Bellón JM; Fontelos PM; de José MI; Gutiérrez MD; Cabrero E; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2005 May; 21(5):398-406. PubMed ID: 15929702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
    Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
    J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.
    Galán I; Jiménez JL; González-Rivera M; De José MI; Navarro ML; Ramos JT; Mellado MJ; Gurbindo MD; Bellón JM; Resino S; Cabrero E; Muñoz-Fernández MA
    AIDS; 2004 Jan; 18(2):247-55. PubMed ID: 15075542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
    Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M;
    J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
    Rudin C; Wolbers M; Nadal D; Rickenbach M; Bucher HC; ;
    Arch Dis Child; 2010 Jun; 95(6):478-81. PubMed ID: 20501542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.
    Machado DM; Gouvêa Ade F; Cardoso MR; Beltrão SV; Cunegundes KS; Bononi F; Almeida F; Cavalheiro K; Angelis DS; Succi RC
    Braz J Infect Dis; 2007 Feb; 11(1):16-9. PubMed ID: 17625720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.
    Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA
    Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.
    Bongiovanni M; Bini T; Casana M; Cicconi P; Tordato F; Monforte AD
    AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1096-105. PubMed ID: 17147495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
    Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.